In this issue:
Dostarlimab for primary advanced endometrial cancer
Pembrolizumab + chemotherapy endometrial cancer
Cost-effectiveness of AI cytology screening
Patient prognosis with SCC of the cervix
Adjuvant chemotherapy as primary treatment for cervical cancer
Lenvatinib + pembrolizumab for endometrial cancer
Trastuzumab deruxtecan for HER2 uterine carcinosarcoma
Paclitaxel and carboplatin use for persistent cervical carcinoma
BMI change on recurrence risk in endometrial cancer
Eribulin monotherapy in advanced cervical cancer
Please login below to download this issue (PDF)